Find Iobitridol manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 136949-58-1, Xenetix, 182ech14uh, 1-n,3-n-bis(2,3-dihydroxypropyl)-5-[[3-hydroxy-2-(hydroxymethyl)propanoyl]amino]-2,4,6-triiodo-1-n,3-n-dimethylbenzene-1,3-dicarboxamide, N,n'-bis(2,3-dihydroxypropyl)-5-(2-(hydroxymethyl)hydracrylamido)-2,4,6-triiodo-n,n'-dimethylisophthalamide, Chebi:31701
Molecular Formula
C20H28I3N3O9
Molecular Weight
835.2  g/mol
InChI Key
YLPBXIKWXNRACS-UHFFFAOYSA-N
FDA UNII
182ECH14UH

Iobitridol
Iobitridol is a water-soluble, tri-iodinated, non-ionic monomeric benzoate derivative and contrast medium used in diagnostic radiography. Upon administration, iobitridol is distributed through the vascular system and interstitial space. Like other organic iodine compounds, this agent blocks x-rays and appears opaque on x-ray film thus, enhancing the visibility of body parts containing this agent. Iobitridol is rapidly removed by the kidneys in an unchanged form, and in cases of renal failure, heterotropic excretion occurs via the biliary route.
1 2D Structure

Iobitridol

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[[3-hydroxy-2-(hydroxymethyl)propanoyl]amino]-2,4,6-triiodo-1-N,3-N-dimethylbenzene-1,3-dicarboxamide
2.1.2 InChI
InChI=1S/C20H28I3N3O9/c1-25(3-10(31)7-29)19(34)12-14(21)13(20(35)26(2)4-11(32)8-30)16(23)17(15(12)22)24-18(33)9(5-27)6-28/h9-11,27-32H,3-8H2,1-2H3,(H,24,33)
2.1.3 InChI Key
YLPBXIKWXNRACS-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)NC(=O)C(CO)CO)I)C(=O)N(C)CC(CO)O)I
2.2 Other Identifiers
2.2.1 UNII
182ECH14UH
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 5-(3-hydroxy-2-hydroxymethylpropionamido)-n,n'-dimethyl-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide

2. Xenetix

2.3.2 Depositor-Supplied Synonyms

1. 136949-58-1

2. Xenetix

3. 182ech14uh

4. 1-n,3-n-bis(2,3-dihydroxypropyl)-5-[[3-hydroxy-2-(hydroxymethyl)propanoyl]amino]-2,4,6-triiodo-1-n,3-n-dimethylbenzene-1,3-dicarboxamide

5. N,n'-bis(2,3-dihydroxypropyl)-5-(2-(hydroxymethyl)hydracrylamido)-2,4,6-triiodo-n,n'-dimethylisophthalamide

6. Chebi:31701

7. 1,3-benzenedicarboxamide, N,n'-bis(2,3-dihydroxypropyl)-5-((5-hydroxy-2-(hydroxymethyl)-1-oxopropyl)amino)-2,4,6-triiodo-n,n'-dimethyl-

8. Iobitridol [inn]

9. Xenetix 300

10. Iobitridol [inn:ban]

11. Unii-182ech14uh

12. Iobitridol [mi]

13. Iobitridol (jan/inn)

14. Iobitridol [jan]

15. Iobitridol [mart.]

16. Iobitridol [who-dd]

17. Schembl23057

18. Chembl2107212

19. Dtxsid90869865

20. Db12407

21. Ncgc00532516-01

22. 5-(3-hydroxy-2-hydroxymethylpropionamido)-n,n'-dimethyl-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide

23. Ft-0627244

24. D01181

25. J-006941

26. Q6062197

27. 1,3-benzenedicarboxamide, N1,n3-bis(2,3-dihydroxypropyl)-5-((3-hydroxy-2-(hydroxymethyl)-1-oxopropyl)amino)-2,4,6-triiodo-n1,n3-dimethyl-

28. 5-(3-hydroxy-2-(hydroxymethyl)-propionamido)-n,n'-dimethyl-n,n'-bis-(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide

29. 5-[3-hydroxy-2-(hydroxymethyl)-propionamido]-n-n -dimethyl-n-n -bis-(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide

30. N,n'-bis(2,3-dihydroxypropyl)-5-((3-hydroxy-2-(hydroxymethyl)-1-oxopropyl)amino)-2,4,6-triiodo-n,n'-dimethyl-1,3-benzenedicarboxamide

31. N,n'-bis(2,3-dihydroxypropyl)-5-{[3-hydroxy-2-(hydroxymethyl)propanoyl]amino}-2,4,6-triiodo-n,n'-dimethylbenzene-1,3-dicarboxamide

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 835.2 g/mol
Molecular Formula C20H28I3N3O9
XLogP3-3
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count9
Rotatable Bond Count12
Exact Mass834.8960 g/mol
Monoisotopic Mass834.8960 g/mol
Topological Polar Surface Area191 Ų
Heavy Atom Count35
Formal Charge0
Complexity675
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count2
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Contrast Media

Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)


4.2 ATC Code

V08AB11

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


V - Various

V08 - Contrast media

V08A - X-ray contrast media, iodinated

V08AB - Watersoluble, nephrotropic, low osmolar x-ray contrast media

V08AB11 - Iobitridol


API SUPPLIERS

read-more
read-more

01

Divis Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health
Not Confirmed
arrow

02

Venkatasai Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health
Not Confirmed
arrow

Venkatasai Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Medlab Asia & Asia Health
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

Conscientia Industrial

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health
Not Confirmed
arrow

Conscientia Industrial

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Medlab Asia & Asia Health
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

CPHI Middle east
Not Confirmed
arrow
arrow
CPHI Middle east
Not Confirmed

Iobitridol

About the Company : Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We...

Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We started business in early 2010, producing and providing products for both human and veterinary health at home and abroad. Conscientia Industrial makes regular productions and also provides custom synthesis, contract manufacturing services. We have series of products, such as Hormones, Prostaglandins, Peptides, Anti-cancer, Anti-tumor, Anti-virus, Anti-diabetic APIs and their related intermediates, impurities, chemicals.
blank

02

CPHI Middle east
Not Confirmed
arrow
arrow
CPHI Middle east
Not Confirmed

Iobitridol

About the Company : Divi's Laboratories Limited is a leading independent contract manufacturer of Active Pharmaceutical Ingredients and registered intermediates. We custom / exclusively manufacture fo...

Divi's Laboratories Limited is a leading independent contract manufacturer of Active Pharmaceutical Ingredients and registered intermediates. We custom / exclusively manufacture for several Big Pharma companies under full cGMP. Customers regularly audit our facilities in areas of quality, EHS, business continuity etc. Unmatched Infrastructure:2 manufacturing sites. Both sites were successfully US-FDA Inspected No of DMFs 373 Pilot Plants30 Production Buildings39 Pharma Suites944 Reactors - 250 L to 30 KLTotal Capacity - 6676 M34 R&D Centers325 Scientists.
blank

03

CPHI Middle east
Not Confirmed
arrow
arrow
CPHI Middle east
Not Confirmed

Iobitridol

About the Company : Established in the year 2013 we help our clients to increase their R&D productivity in a cost-effective manner. We address a wide spectrum of client needs across the drug discovery...

Established in the year 2013 we help our clients to increase their R&D productivity in a cost-effective manner. We address a wide spectrum of client needs across the drug discovery and development value chain, which include: Medicinal Chemistry, Custom Synthesis, and Process R&D, Toxicology, Clinical Research, and Analytical Testing. Quality has been the major factor behind Venkatasai life sciences success in the wide competitive arena. We also ensure that all the products conform to strict quality standards. Owing to this, we are counted as one of the first and foremost choice of our clients that are spread across the world.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty